Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Isoray, Inc.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback.
- Implantable Devices
- Other Names / Subsidiaries
- IsoRay Medical, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.